Retrospective study of Parkinson's Disease Psychosis patients treated with Pimavanserin.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimavanserin (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

29 Mar 2019 Results evaluating efficacy and tolerability of pimavanserin in patients with parkinson's disease related psychosis published in the Drugs and Aging
07 May 2018 New trial record
27 Apr 2018 Results (n=59) presented at the 70th Annual Meeting of the American Academy of Neurology

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight